Allogene Therapeutics CFO sells 36,342 shares

The chief financial officer’s sale covered tax withholding tied to restricted-stock-unit vesting and was required under the issuer’s equity incentive plan.

Rhea-AI Filing Summary

Allogene Therapeutics, Inc. Chief Financial Officer Geoffrey M. Parker sold 36,342 common shares on October 21, 2026, at $1.34 per share. The sale covered tax withholding obligations tied to vesting restricted stock units and was required under the issuer’s equity incentive plan, not a discretionary trade. Reported holdings after the transaction were 1,045,877 shares; that figure reflects forfeiture of 195,000 performance RSU shares and includes 12,500 shares acquired March 15, 2026, and 11,924 acquired September 15, 2026, through the employee stock purchase program. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Net Seller: 36,342 shares

Net Sell 1 txn

Insider Parker Geoffrey M.

Role CHIEF FINANCIAL OFFICER

Sold 36,342 shs ($49K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3, F4	36,342	$1.34	$49K

Holdings After Transaction: Common Stock — 1,045,877 shares (Direct)

Footnotes (4)

1. F1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
2. F2. Reflects forfeiture of 195,000 shares subject to performance RSUs granted to the Reporting Person on October 10, 2023.
3. F3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.
4. F4. Includes 11,924 shares of the Issuer's common stock acquired by the reporting person on September 15, 2026 pursuant to an employee stock purchase program.

Key Figures

Common shares sold: 36,342 shares Sale price: $1.34 per share Shares held after transaction: 1,045,877 shares +3 more

6 metrics

Common shares sold 36,342 shares October 21, 2026

Sale price $1.34 per share October 21, 2026

Shares held after transaction 1,045,877 shares Reported following the October 21, 2026 transaction

Performance RSU shares forfeited 195,000 shares Performance RSUs granted October 10, 2023

Shares acquired through employee stock purchase program 12,500 shares Acquired March 15, 2026

Shares acquired through employee stock purchase program 11,924 shares Acquired September 15, 2026

Key Terms

sell to cover, restricted stock units, performance RSUs, employee stock purchase program

4 terms

sell to cover financial

"funded by a sell to cover transaction"

Sell to cover is when a person who receives company stock through options or awards sells just enough shares immediately to pay required taxes, exercise costs, or fees, keeping the rest. Think of it like cashing part of a bonus to cover the tax bill so you can keep the remainder. For investors, it can create predictable small selling pressure and slightly change the number of shares actually held by insiders without increasing long‑term dilution.

restricted stock units financial

"in connection with the vesting of restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

performance RSUs financial

"shares subject to performance RSUs"

Performance RSUs are promises to deliver company shares to executives or employees only if the business meets preset goals such as revenue, profit, stock price, or operational targets. They matter to investors because they align management pay with measurable company results and can affect the number of shares outstanding and future earnings per share once the shares are issued. Think of them as a bonus paid in stock that only arrives if the team hits the agreed milestones.

employee stock purchase program financial

"pursuant to an employee stock purchase program"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many ALLO shares did the chief financial officer sell, and at what price?

Geoffrey M. Parker, Allogene Therapeutics’ chief financial officer, sold 36,342 common shares on October 21, 2026, at $1.34 per share. Reported holdings after the transaction were 1,045,877 shares.

Why did the ALLO chief financial officer sell shares?

The sale covered tax withholding obligations tied to restricted stock units vesting and was required under Allogene Therapeutics’ equity incentive plan’s sell to cover election, rather than a discretionary trade. No Rule 10b5-1 plan is reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/23/2026 - 04:56 PM EDT Accepted by SEC EDGAR 10/23/2026 - 04:48 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Parker Geoffrey M.

(Last) (First) (Middle)

210 EAST GRAND AVE

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Allogene Therapeutics, Inc. [ ALLO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF FINANCIAL OFFICER

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/21/2026		S		36,342(1)	D	$1.34	1,045,877(2)(3)(4)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.

2. Reflects forfeiture of 195,000 shares subject to performance RSUs granted to the Reporting Person on October 10, 2023.

3. Includes 12,500 shares of the Issuer's common stock acquired by the reporting person on March 15, 2026 pursuant to an employee stock purchase program.

4. Includes 11,924 shares of the Issuer's common stock acquired by the reporting person on September 15, 2026 pursuant to an employee stock purchase program.

Remarks:

	/s/Earl Douglas, Attorney-in-Fact	10/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)